Achieving end-to-end success in the clinic: Pfizer's learnings on R&D productivity.
Drug Discov Today
; 27(3): 697-704, 2022 03.
Article
in English
| MEDLINE | ID: covidwho-1568633
ABSTRACT
Over the past decade, Pfizer has focused efforts to improve its research and development (R&D) productivity. By the end of 2020, Pfizer had achieved an industry-leading clinical success rate of 21%, a tenfold increase from 2% in 2010 and well above the industry benchmark of â¼11%. The company had also maintained the quality of innovation, because 75% of its approvals between 2016 and 2020 had at least one expedited regulatory designation (e.g., Breakthrough Therapy). Pfizer's Signs of Clinical Activity (SOCA) paradigm enabled better decision-making and, along with other drivers (biology and modality), contributed to this productivity improvement. These laid a strong foundation for the rapid and effective development of the Coronavirus 2019 (COVID-19) vaccine with BioNTech, as well as the antiviral candidate Paxlovid™, under the company's 'lightspeed' paradigm.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Research
/
Drug Industry
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Drug Discov Today
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2022
Document Type:
Article
Affiliation country:
J.drudis.2021.12.010
Similar
MEDLINE
...
LILACS
LIS